Which has stronger valuation and earnings, GNLX or PRME?

Genelux has higher earnings, but lower revenue than Prime Medicine. Genelux is trading at a lower price-to-earnings ratio than Prime Medicine, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Genelux $10K 13,115.70 -$32.15M -$0.85 N/A Prime Medicine $4.63M 111.77 -$201.14M -$1.23 N/A

Is GNLX or PRME more profitable?

Genelux has a net margin of 0.00% compared to Prime Medicine's net margin of -4,917.55%. Genelux's return on equity of -174.55% beat Prime Medicine's return on equity. Company Net Margins Return on Equity Return on Assets Genelux N/A -174.55% -123.65% Prime Medicine -4,917.55% -188.82% -60.97%

Does the media favor GNLX or PRME?

In the previous week, Prime Medicine had 3 more articles in the media than Genelux. MarketBeat recorded 4 mentions for Prime Medicine and 1 mentions for Genelux. Prime Medicine's average media sentiment score of 0.81 beat Genelux's score of 0.00 indicating that Prime Medicine is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Genelux 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Prime Medicine 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor GNLX or SLN?

In the previous week, Silence Therapeutics had 2 more articles in the media than Genelux. MarketBeat recorded 3 mentions for Silence Therapeutics and 1 mentions for Genelux. Silence Therapeutics' average media sentiment score of 1.00 beat Genelux's score of 0.00 indicating that Silence Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Genelux 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Silence Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is GNLX or DNA more profitable?

Genelux has a net margin of 0.00% compared to Ginkgo Bioworks' net margin of -215.41%. Ginkgo Bioworks' return on equity of -56.08% beat Genelux's return on equity. Company Net Margins Return on Equity Return on Assets Genelux N/A -174.55% -123.65% Ginkgo Bioworks -215.41% -56.08% -26.06%

Does the media prefer GNLX or DNA?

In the previous week, Genelux and Genelux both had 1 articles in the media. Genelux's average media sentiment score of 0.00 equaled Ginkgo Bioworks'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Genelux 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Ginkgo Bioworks 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is GNLX or SPRY more profitable?

Genelux has a net margin of 0.00% compared to ARS Pharmaceuticals' net margin of -200.00%. ARS Pharmaceuticals' return on equity of -153.61% beat Genelux's return on equity. Company Net Margins Return on Equity Return on Assets Genelux N/A -174.55% -123.65% ARS Pharmaceuticals -200.00% -153.61% -60.85%

Does the media favor GNLX or SPRY?

In the previous week, ARS Pharmaceuticals had 6 more articles in the media than Genelux. MarketBeat recorded 7 mentions for ARS Pharmaceuticals and 1 mentions for Genelux. ARS Pharmaceuticals' average media sentiment score of 0.90 beat Genelux's score of 0.00 indicating that ARS Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Genelux 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ARS Pharmaceuticals 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Which has better valuation and earnings, GNLX or TLRY?

Genelux has higher earnings, but lower revenue than Tilray Brands. Tilray Brands is trading at a lower price-to-earnings ratio than Genelux, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Genelux $10K 13,115.70 -$32.15M -$0.85 N/A Tilray Brands $915.45M 0.61 -$121.40M -$1.08 N/A

Is GNLX or TLRY more profitable?

Genelux has a net margin of 0.00% compared to Tilray Brands' net margin of -13.11%. Tilray Brands' return on equity of -7.76% beat Genelux's return on equity. Company Net Margins Return on Equity Return on Assets Genelux N/A -174.55% -123.65% Tilray Brands -13.11% -7.76% -5.59%

Does the media favor GNLX or TLRY?

In the previous week, Tilray Brands had 32 more articles in the media than Genelux. MarketBeat recorded 33 mentions for Tilray Brands and 1 mentions for Genelux. Tilray Brands' average media sentiment score of 0.48 beat Genelux's score of 0.00 indicating that Tilray Brands is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Genelux 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Tilray Brands 11 Very Positive mention(s) 7 Positive mention(s) 9 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral

Genelux (GNLX) Competitors

$2.92 -0.02 (-0.51%)

As of 11:58 AM Eastern

Compare

GNLX vs. PRME, SLN, DNA, SPRY, and TLRY

Should you buy Genelux stock or one of its competitors? MarketBeat compares Genelux with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Genelux include Prime Medicine (PRME), Silence Therapeutics (SLN), Ginkgo Bioworks (DNA), ARS Pharmaceuticals (SPRY), and Tilray Brands (TLRY).

How does Genelux compare to Prime Medicine?

Genelux (NASDAQ:GNLX) and Prime Medicine (NASDAQ:PRME) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, media sentiment, analyst recommendations, dividends and profitability.

In the previous week, Prime Medicine had 3 more articles in the media than Genelux. MarketBeat recorded 4 mentions for Prime Medicine and 1 mentions for Genelux. Prime Medicine's average media sentiment score of 0.81 beat Genelux's score of 0.00 indicating that Prime Medicine is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genelux	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Prime Medicine	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Genelux has a beta of 0.6, suggesting that its stock price is 40% less volatile than the broader market. Comparatively, Prime Medicine has a beta of 2.31, suggesting that its stock price is 131% more volatile than the broader market.

Genelux has higher earnings, but lower revenue than Prime Medicine. Genelux is trading at a lower price-to-earnings ratio than Prime Medicine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genelux	$10K	13,115.70	-$32.15M	-$0.85	N/A
Prime Medicine	$4.63M	111.77	-$201.14M	-$1.23	N/A

37.3% of Genelux shares are held by institutional investors. Comparatively, 70.4% of Prime Medicine shares are held by institutional investors. 7.5% of Genelux shares are held by company insiders. Comparatively, 16.0% of Prime Medicine shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Genelux presently has a consensus price target of $18.00, indicating a potential upside of 515.38%. Prime Medicine has a consensus price target of $7.53, indicating a potential upside of 162.87%. Given Genelux's higher possible upside, equities analysts clearly believe Genelux is more favorable than Prime Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genelux	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Prime Medicine	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Genelux has a net margin of 0.00% compared to Prime Medicine's net margin of -4,917.55%. Genelux's return on equity of -174.55% beat Prime Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genelux	N/A	-174.55%	-123.65%
Prime Medicine	-4,917.55%	-188.82%	-60.97%

Summary

Prime Medicine beats Genelux on 11 of the 17 factors compared between the two stocks.

How does Genelux compare to Silence Therapeutics?

Genelux (NASDAQ:GNLX) and Silence Therapeutics (NASDAQ:SLN) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, institutional ownership, valuation, analyst recommendations, risk and media sentiment.

Genelux has a beta of 0.6, suggesting that its share price is 40% less volatile than the broader market. Comparatively, Silence Therapeutics has a beta of 1.38, suggesting that its share price is 38% more volatile than the broader market.

Genelux presently has a consensus target price of $18.00, suggesting a potential upside of 515.38%. Silence Therapeutics has a consensus target price of $55.00, suggesting a potential upside of 389.11%. Given Genelux's higher possible upside, research analysts plainly believe Genelux is more favorable than Silence Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genelux	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Silence Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

Genelux has a net margin of 0.00% compared to Silence Therapeutics' net margin of -8,943.86%. Silence Therapeutics' return on equity of -105.34% beat Genelux's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genelux	N/A	-174.55%	-123.65%
Silence Therapeutics	-8,943.86%	-105.34%	-52.79%

37.3% of Genelux shares are owned by institutional investors. Comparatively, 98.7% of Silence Therapeutics shares are owned by institutional investors. 7.5% of Genelux shares are owned by insiders. Comparatively, 3.0% of Silence Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Silence Therapeutics had 2 more articles in the media than Genelux. MarketBeat recorded 3 mentions for Silence Therapeutics and 1 mentions for Genelux. Silence Therapeutics' average media sentiment score of 1.00 beat Genelux's score of 0.00 indicating that Silence Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genelux	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Silence Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Genelux has higher earnings, but lower revenue than Silence Therapeutics. Silence Therapeutics is trading at a lower price-to-earnings ratio than Genelux, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genelux	$10K	13,115.70	-$32.15M	-$0.85	N/A
Silence Therapeutics	$839K	633.08	-$88.61M	-$1.59	N/A

Summary

Silence Therapeutics beats Genelux on 10 of the 17 factors compared between the two stocks.

How does Genelux compare to Ginkgo Bioworks?

Genelux (NASDAQ:GNLX) and Ginkgo Bioworks (NYSE:DNA) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment, valuation and dividends.

Genelux currently has a consensus target price of $18.00, indicating a potential upside of 515.38%. Ginkgo Bioworks has a consensus target price of $8.50, indicating a potential downside of 3.13%. Given Genelux's stronger consensus rating and higher possible upside, research analysts clearly believe Genelux is more favorable than Ginkgo Bioworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genelux	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Ginkgo Bioworks	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67

Genelux has a beta of 0.6, indicating that its share price is 40% less volatile than the broader market. Comparatively, Ginkgo Bioworks has a beta of 1.77, indicating that its share price is 77% more volatile than the broader market.

In the previous week, Genelux and Genelux both had 1 articles in the media. Genelux's average media sentiment score of 0.00 equaled Ginkgo Bioworks'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genelux	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ginkgo Bioworks	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Genelux has a net margin of 0.00% compared to Ginkgo Bioworks' net margin of -215.41%. Ginkgo Bioworks' return on equity of -56.08% beat Genelux's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genelux	N/A	-174.55%	-123.65%
Ginkgo Bioworks	-215.41%	-56.08%	-26.06%

Genelux has higher earnings, but lower revenue than Ginkgo Bioworks. Genelux is trading at a lower price-to-earnings ratio than Ginkgo Bioworks, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genelux	$10K	13,115.70	-$32.15M	-$0.85	N/A
Ginkgo Bioworks	$151.40M	3.79	-$312.76M	-$5.36	N/A

37.3% of Genelux shares are owned by institutional investors. Comparatively, 78.6% of Ginkgo Bioworks shares are owned by institutional investors. 7.5% of Genelux shares are owned by company insiders. Comparatively, 12.7% of Ginkgo Bioworks shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Genelux and Ginkgo Bioworks tied by winning 7 of the 14 factors compared between the two stocks.

How does Genelux compare to ARS Pharmaceuticals?

Genelux (NASDAQ:GNLX) and ARS Pharmaceuticals (NASDAQ:SPRY) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, profitability, institutional ownership, media sentiment, earnings and analyst recommendations.

37.3% of Genelux shares are owned by institutional investors. Comparatively, 68.2% of ARS Pharmaceuticals shares are owned by institutional investors. 7.5% of Genelux shares are owned by company insiders. Comparatively, 33.8% of ARS Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Genelux has a beta of 0.6, meaning that its share price is 40% less volatile than the broader market. Comparatively, ARS Pharmaceuticals has a beta of 0.98, meaning that its share price is 2% less volatile than the broader market.

In the previous week, ARS Pharmaceuticals had 6 more articles in the media than Genelux. MarketBeat recorded 7 mentions for ARS Pharmaceuticals and 1 mentions for Genelux. ARS Pharmaceuticals' average media sentiment score of 0.90 beat Genelux's score of 0.00 indicating that ARS Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genelux	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ARS Pharmaceuticals	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Genelux currently has a consensus target price of $18.00, indicating a potential upside of 515.38%. ARS Pharmaceuticals has a consensus target price of $28.20, indicating a potential upside of 423.29%. Given Genelux's higher possible upside, research analysts plainly believe Genelux is more favorable than ARS Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genelux	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
ARS Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Genelux has higher earnings, but lower revenue than ARS Pharmaceuticals. Genelux is trading at a lower price-to-earnings ratio than ARS Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genelux	$10K	13,115.70	-$32.15M	-$0.85	N/A
ARS Pharmaceuticals	$84.28M	6.35	-$171.30M	-$2.01	N/A

Genelux has a net margin of 0.00% compared to ARS Pharmaceuticals' net margin of -200.00%. ARS Pharmaceuticals' return on equity of -153.61% beat Genelux's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genelux	N/A	-174.55%	-123.65%
ARS Pharmaceuticals	-200.00%	-153.61%	-60.85%

Summary

ARS Pharmaceuticals beats Genelux on 10 of the 15 factors compared between the two stocks.

How does Genelux compare to Tilray Brands?

Genelux (NASDAQ:GNLX) and Tilray Brands (NASDAQ:TLRY) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, dividends, profitability, earnings, valuation and media sentiment.

In the previous week, Tilray Brands had 32 more articles in the media than Genelux. MarketBeat recorded 33 mentions for Tilray Brands and 1 mentions for Genelux. Tilray Brands' average media sentiment score of 0.48 beat Genelux's score of 0.00 indicating that Tilray Brands is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genelux	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tilray Brands	11 Very Positive mention(s)	7 Positive mention(s)	9 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral

Genelux has higher earnings, but lower revenue than Tilray Brands. Tilray Brands is trading at a lower price-to-earnings ratio than Genelux, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genelux	$10K	13,115.70	-$32.15M	-$0.85	N/A
Tilray Brands	$915.45M	0.61	-$121.40M	-$1.08	N/A

Genelux has a net margin of 0.00% compared to Tilray Brands' net margin of -13.11%. Tilray Brands' return on equity of -7.76% beat Genelux's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genelux	N/A	-174.55%	-123.65%
Tilray Brands	-13.11%	-7.76%	-5.59%

Genelux has a beta of 0.6, suggesting that its share price is 40% less volatile than the broader market. Comparatively, Tilray Brands has a beta of 1.9, suggesting that its share price is 90% more volatile than the broader market.

37.3% of Genelux shares are owned by institutional investors. Comparatively, 9.4% of Tilray Brands shares are owned by institutional investors. 7.5% of Genelux shares are owned by insiders. Comparatively, 0.8% of Tilray Brands shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Genelux currently has a consensus price target of $18.00, suggesting a potential upside of 515.38%. Tilray Brands has a consensus price target of $11.00, suggesting a potential upside of 130.70%. Given Genelux's higher possible upside, equities analysts clearly believe Genelux is more favorable than Tilray Brands.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genelux	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Tilray Brands	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.50

Summary

Genelux beats Tilray Brands on 8 of the 15 factors compared between the two stocks.

Get Genelux News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GNLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GNLX vs. The Competition

Export

Metric	Genelux	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$131.38M	$3.52B	$6.79B	$12.63B
Dividend Yield	N/A	3.78%	2.59%	10.03%
P/E Ratio	-3.45	7.39	282.14	25.05
Price / Sales	13,115.70	1,212.47	573.43	80.07
Price / Cash	N/A	44.80	28.60	46.71
Price / Book	9.75	17.11	11.09	6.19
Net Income	-$32.15M	-$12.56M	$3.49B	$347.61M
7 Day Performance	-0.85%	-0.59%	0.42%	0.74%
1 Month Performance	-2.17%	-7.44%	-4.33%	-3.72%
1 Year Performance	-16.67%	49.84%	63.09%	20.27%

Genelux Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GNLX Genelux	1.4676 of 5 stars	$2.93 -0.5%	$18.00 +515.4%	-16.2%	$131.38M	$10K	N/A	10	Positive News Upcoming Earnings Gap Up
PRME Prime Medicine	3.414 of 5 stars	$2.94 -2.8%	$7.53 +156.6%	N/A	$528.31M	$4.63M	N/A	N/A	News Coverage
SLN Silence Therapeutics	3.449 of 5 stars	$11.22 -3.5%	$55.00 +390.4%	+70.0%	$526.34M	$839K	N/A	100	Upcoming Earnings
DNA Ginkgo Bioworks	0.1709 of 5 stars	$8.00 -1.2%	$8.50 +6.3%	-33.7%	$520.76M	$151.40M	N/A	640	Upcoming Earnings
SPRY ARS Pharmaceuticals	2.7347 of 5 stars	$5.24 -7.0%	$28.20 +438.7%	-70.1%	$519.84M	$84.28M	N/A	90

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GNLX) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Genelux (GNLX) Competitors

GNLX vs. PRME, SLN, DNA, SPRY, and TLRY

How does Genelux compare to Prime Medicine?

Summary

How does Genelux compare to Silence Therapeutics?

Summary

How does Genelux compare to Ginkgo Bioworks?

Summary

How does Genelux compare to ARS Pharmaceuticals?

Summary

How does Genelux compare to Tilray Brands?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GNLX vs. The Competition

Genelux Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Genelux (GNLX) Competitors

GNLX vs. PRME, SLN, DNA, SPRY, and TLRY

How does Genelux compare to Prime Medicine?

Does the media favor GNLX or PRME?

Which has more volatility and risk, GNLX or PRME?

Which has stronger valuation and earnings, GNLX or PRME?

Do institutionals & insiders have more ownership in GNLX or PRME?

Do analysts rate GNLX or PRME?

Is GNLX or PRME more profitable?

Summary

How does Genelux compare to Silence Therapeutics?

Which has more volatility and risk, GNLX or SLN?

Do analysts rate GNLX or SLN?

Is GNLX or SLN more profitable?

Do institutionals & insiders hold more shares of GNLX or SLN?

Does the media favor GNLX or SLN?

Which has preferable valuation and earnings, GNLX or SLN?

Summary

How does Genelux compare to Ginkgo Bioworks?

Do analysts rate GNLX or DNA?

Which has more volatility & risk, GNLX or DNA?

Does the media prefer GNLX or DNA?

Is GNLX or DNA more profitable?

Which has preferable earnings and valuation, GNLX or DNA?

Do insiders and institutionals believe in GNLX or DNA?

Summary

How does Genelux compare to ARS Pharmaceuticals?

Do institutionals and insiders believe in GNLX or SPRY?

Which has more volatility & risk, GNLX or SPRY?

Does the media favor GNLX or SPRY?

Do analysts rate GNLX or SPRY?

Which has higher earnings & valuation, GNLX or SPRY?

Is GNLX or SPRY more profitable?

Summary

How does Genelux compare to Tilray Brands?

Does the media favor GNLX or TLRY?

Which has better valuation and earnings, GNLX or TLRY?

Is GNLX or TLRY more profitable?

Which has more risk & volatility, GNLX or TLRY?

Do insiders & institutionals have more ownership in GNLX or TLRY?

Do analysts recommend GNLX or TLRY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GNLX vs. The Competition

Genelux Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools